Truvian Health Appoints Dr. Tina S. Nova to Board; Ties to Ligand Pharmaceuticals

Truvian Health Strengthens Board with Appointment of Dr. Tina S. Nova

Truvian Health, a company dedicated to transforming blood diagnostics, recently announces the addition of Dr. Tina S. Nova to its Board of Directors. Dr. Nova brings over two decades of extensive experience in the fields of diagnostics and biotechnology, positioning her as a valuable asset for Truvian. Her previous roles include serving as president and CEO of Decipher Biosciences, where she played a significant part in the company's acquisition by Veracyte for $600 million in 2021. Dr. Nova's rich history includes leadership positions at Illumina and co-founding Genoptix Medical Laboratory, which successfully navigated an IPO and was later acquired by Novartis AG.

Dr. Nova's expertise is particularly relevant as Truvian Health advances its innovative blood testing platform. She has previously collaborated with Ligand Pharmaceuticals, among other notable companies in the diagnostics space, which enhances her understanding of the challenges and opportunities within the industry. Her enthusiasm for Truvian’s mission to provide accurate and personalized lab results reflects a commitment to revolutionizing healthcare. With her background, Dr. Nova is poised to guide the company as it seeks to make blood testing more accessible, ultimately leading to improved health outcomes for patients.

Truvian Health's CEO, Jay Srinivasan, underscores the significance of Dr. Nova's appointment, highlighting her visionary leadership and expertise as essential to the company's strategic goals. As Truvian works toward regulatory approvals for its comprehensive benchtop solution, the company's ambition is to integrate this technology into clinics, pharmacies, and doctors' offices. This initiative aims to facilitate a shift towards personalized medicine, ensuring that tailored treatment options become the norm in healthcare.

In addition to her role at Truvian, Dr. Nova serves on several boards, including those of Azenta and Exagen, further illustrating her commitment to advancing healthcare. The company’s focus on accessible blood testing aligns with the broader trend in biotechnology that emphasizes personalized medicine, an area where Dr. Nova’s leadership can significantly impact. As Truvian Health continues its mission, the appointment of Dr. Nova marks a pivotal step in enhancing its capabilities and expanding its reach in the diagnostics market.